Case Study In Bioprocess Development New! — A Mab A

Protein A capacity remains stable at 40 g/L resin. Elution at pH 3.5 yields 95% purity with <0.1% aggregates. However, the low-pH elution creates a new problem: inactivation of a small fraction of Mab-X, reducing potency by 10%.

: It helped popularize the "platform approach" in mAb production, which significantly reduces the time from gene to clinical trials. Critiques & Limitations A Mab A Case Study In Bioprocess Development

The primary goal of the A-Mab study is to move away from "quality by testing" (verifying quality at the end of the process) toward a systematic, risk-based approach where quality is built into the process from the start. Protein A capacity remains stable at 40 g/L resin

: Establishing a "Design Space" where process parameters can vary without affecting product quality. : It helped popularize the "platform approach" in

A Mab was filled into 10 mL Type I glass vials with a 20% overfill. The filling line operated at 300 vials/minute under Grade A isolators. Freeze-thaw studies showed stability for 5 cycles (typical for bulk freezing).